Willis M, Pearson O, Illes Z, Sejbaek T, Nielsen C, Duddy M, Petheram K, van Munster C, Killestein J, Malmeström C, Tallantyre E, Robertson N. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017 Jan 10;4(2):e320.
Yesterday the "Headmaster" complained my post was too complicated.
So maybe we should just do highlights for the people that like their info in sound bites
- Fingolimod traps T and B cells in Lymph Glands
- Alemtuzumab kills T and B cells in the Blood
- However alemtuzumab is not that effective at killing cells in lymph glands and bone marrow
- Fingolimod can stop Alemtuzumab working
- Be careful what you do when you switch treatment from fingolimod !
- More evidence that B cells are the main targets for treatment..hang on shouldn't this be T cells!
- Maybe more evidence for alemtuzmab neutralizing antibodies
However, where is the analysis, explanation? What do you think?
This rebound will not occur in every body. In this study
there were 36 six people, who had used fingolimod before alemtuzumab and the disease activity was seen in 9 people i.e. 25%. Remember, alemtuzumab is not infallible and relapse (4% in the cardiff cohort) in the first year occurs.
Of these people 8/9 were disease free after the second set of infusions
Labels: Alemtuzumab, fingolimod